<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411994</url>
  </required_header>
  <id_info>
    <org_study_id>KIT601714</org_study_id>
    <nct_id>NCT02411994</nct_id>
  </id_info>
  <brief_title>Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria</brief_title>
  <acronym>PAAL</acronym>
  <official_title>Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Tropical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Tropical Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of pyronaridine-artesunate and
      artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in
      Kenyan children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>day 28 after initial dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR-corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>day 42 after initial dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>crude adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>day 28, day 42 after initial dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parasite clearance time</measure>
    <time_frame>up to 7 days after initial dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gametocyte clearance time</measure>
    <time_frame>up to 7 days after initial dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission potential to mosquitos</measure>
    <time_frame>day 7 after initial dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine-artesunate</intervention_name>
    <arm_group_label>Pyronaridine-artesunate</arm_group_label>
    <other_name>Pyramax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 6 months and 12 years old, with a body weight of ≥5 kg;

          -  Living in the catchment area of the study (within a radius of ~10 km from St. Jude's
             Clinic, Mbita, Kenya);

          -  Having microscopically confirmed P. falciparum mono-infection (asexual parasite
             density 1,000-200,000 µL-1).

        Exclusion Criteria:

          -  Signs and symptoms of severe malaria (according to WHO criteria for severe malaria,
             (WHO 2012)) or any other severe illness necessitating parenteral treatment;

          -  Mixed Plasmodium infection;

          -  Clinically suspected (oedema, jaundice and/or ascites) or reported hepatic and/or
             renal impairment (any cause, as reported by parents/guardians and/or evident from
             medical history);

          -  Having anaemia with an Hb &lt;6 g/dL;

          -  Evidence of severe malnutrition (severe wasting: z-score weight for age &lt;-3 and
             severe stunting: z-score height for age &lt;-3 (WHO 2009b));

          -  Having received anti-malarial therapy in the previous two weeks;

          -  Known history of hypersensitivity, allergic or adverse reactions to artesunate,
             artemether-lumefantrine or other artemisinins;

          -  Participating in other anti-malarial drug intervention studies;

          -  Previous participation in the PAAL study, e.g. in the previous transmission season
             (each individual child can only take part in this study once);

          -  Not being available for follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Sawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre of Insect Physiology and Ecology, Mbita, Kenya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Roth, MSc</last_name>
    <phone>+31(0)205665442</phone>
    <email>j.roth@kit.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Mens, PhD</last_name>
    <phone>+31(0)205665463</phone>
    <email>p.mens@kit.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Jude's Clinic, ICIPE</name>
      <address>
        <city>Mbita</city>
        <zip>30-40305</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Sawa, MD, PhD</last_name>
      <phone>0722369254</phone>
      <email>psawa@icipe.org</email>
    </contact>
    <contact_backup>
      <last_name>Johanna Roth, MSc</last_name>
      <phone>0790498290</phone>
      <email>j.roth@kit.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 2, 2015</lastchanged_date>
  <firstreceived_date>April 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
